{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:51:13Z","timestamp":1792266673179,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>BCR-ABL1, resulting from t(9;22), is the oncogenic driver of chronic myeloid leukemia and the therapeutic target of the disease. Molecular studies have been the gold standard modality for patient assessment since the advent of tyrosine kinase inhibitor therapy. In spite of that, there are cytogenetic abnormalities that can render the disease unresponsive to conventional therapy, thus making cytogenetics an important component of patient management guidelines.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>We present a case of a Tajik, Afghan patient with chronic myeloid leukemia with del(6)(q23.3q27), t(9;22)(q34;q11.2), monosomy 11, monosomy 12, and marker chromosome who, despite having typical clinical and hematological disease with initial response to therapy, progressed to blast crisis very early and thus required special interventions.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Cytogenetic monitoring is an important pillar in the management of patients with chronic myeloid leukemia that cannot be ignored. It should therefore be a part of patient management not only during diagnosis but also during management. We present an unusual cytogenetic abnormality in a patient with chronic myeloid leukemia that resulted in early disease progression.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-02539-x","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:06:57Z","timestamp":1606435617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Complex cytogenetic abnormalities in chronic myeloid leukemia resulting in early progression to blast crisis: a case report"],"prefix":"10.1186","volume":"14","author":[{"given":"Haider Ali","family":"Malakzai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Maseh","family":"Haidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Sami","family":"Ibrahimkhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"issue":"2","key":"2539_CR1","first-page":"149","volume":"41","author":"AM Haidary","year":"2019","unstructured":"Haidary AM, Azma Z, Ithnin A, Alauddin H, Rafeah Tumian N, Tamil AM, et al. FISH versus real-time quantitative PCR for monitoring of minimal residual disease in chronic myeloid leukaemia patients on tyrosine kinase inhibitor therapy. Malays J Pathol. 2019;41(2):149\u201360.","journal-title":"Malays J Pathol"},{"issue":"Suppl 1","key":"2539_CR2","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.leukres.2003.10.005","volume":"28","author":"RA Van Etten","year":"2004","unstructured":"Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res. 2004;28(Suppl 1):S21\u20138.","journal-title":"Leuk Res"},{"issue":"12","key":"2539_CR3","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","volume":"17","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17(12):2401\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"2539_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","volume":"135","author":"CP Loren","year":"2015","unstructured":"Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber A, et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res. 2015;135(1):155\u201360.","journal-title":"Thromb Res"},{"issue":"3","key":"2539_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","volume":"29","author":"R Hehlmann","year":"2016","unstructured":"Hehlmann R, Sau\u00dfele S, Voskanyan A, Silver RT. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016;29(3):295\u2013307.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"2539_CR6","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172\u20135.","journal-title":"Leukemia"},{"issue":"1","key":"2539_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17\u201323.","journal-title":"Blood"},{"issue":"1","key":"2539_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/cas.13430","volume":"109","author":"T Kumagai","year":"2018","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109(1):182\u201392.","journal-title":"Cancer Sci"},{"key":"2539_CR9","volume-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi ASR. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2017.","edition":"4"},{"issue":"2","key":"2539_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11899-016-0303-8","volume":"11","author":"CC Yeung","year":"2016","unstructured":"Yeung CC, Egan D, Radich J. New methodologies in the molecular monitoring of CML. Curr Hematol Malig Rep. 2016;11(2):94\u2013101.","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"2539_CR11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1046\/j.1365-2141.1998.00823.x","volume":"102","author":"E Mensink","year":"1998","unstructured":"Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998;102(3):768\u201374.","journal-title":"Br J Haematol"},{"issue":"2","key":"2539_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91(2):252\u201365.","journal-title":"Am J Hematol"},{"issue":"3","key":"2539_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.13966","volume":"173","author":"S Soverini","year":"2016","unstructured":"Soverini S, De Benedittis C, Mancini M, Martinelli G. Present and future of molecular monitoring in chronic myeloid leukaemia. Br J Haematol. 2016;173(3):337\u201349.","journal-title":"Br J Haematol"},{"key":"2539_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-4-431-55714-2_6","volume-title":"Molecular pathogenesis and treatment of chronic myelogenous leukemia","author":"N Usui","year":"2016","unstructured":"Usui N. Updated European LeukemiaNet recommendations for the management of CML. In: Kizaki M, editor. Molecular pathogenesis and treatment of chronic myelogenous leukemia. Tokyo: Springer; 2016. p. 81\u2013100."},{"issue":"11","key":"2539_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1177\/1060028013501144","volume":"47","author":"CL Shamroe","year":"2013","unstructured":"Shamroe CL, Comeau JM. Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother. 2013;47(11):1540\u20136.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2539_CR16","doi-asserted-by":"publisher","first-page":"e0207170","DOI":"10.1371\/journal.pone.0207170","volume":"14","author":"H Kitamura","year":"2019","unstructured":"Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri M, Misawa S, Horii T, Kawaguchi A, Ohsaka A, Kimura S. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib. PLoS One. 2019;14(3):e0207170.","journal-title":"PLoS One"},{"issue":"6","key":"2539_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"7","key":"2539_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","volume":"74","author":"SM Hoy","year":"2014","unstructured":"Hoy SM. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2014;74(7):793\u2013806.","journal-title":"Drugs"},{"issue":"12","key":"2539_CR19","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","volume":"94","author":"A Fabarius","year":"2015","unstructured":"Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015;94(12):2015\u201324.","journal-title":"Ann Hematol"},{"issue":"5","key":"2539_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1034\/j.1600-0609.2002.00671.x","volume":"68","author":"YJ Kim","year":"2002","unstructured":"Kim YJ, Kim DW, Lee S, Kim HJ, Kim YL, Hwang JY, et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol. 2002;68(5):272\u201380.","journal-title":"Eur J Haematol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-020-02539-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:38:51Z","timestamp":1606437531000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02539-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2539"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02539-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"1 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}